Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 532

1.

iPSC-derived functional human neuromuscular junctions model the pathophysiology of neuromuscular diseases.

Lin CY, Yoshida M, Li LT, Ikenaka A, Oshima S, Nakagawa K, Sakurai H, Matsui E, Nakahata T, Saito MK.

JCI Insight. 2019 Sep 19;4(18). pii: 124299. doi: 10.1172/jci.insight.124299.

2.

Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.

Shigemura T, Matsuda K, Kurata T, Sakashita K, Okuno Y, Muramatsu H, Yue F, Ebihara Y, Tsuji K, Sasaki K, Nakahata T, Nakazawa Y, Koike K.

Br J Haematol. 2019 Oct;187(2):163-173. doi: 10.1111/bjh.16060. Epub 2019 Jun 20.

PMID:
31222725
3.

Overexpression of GATA2 Enhances Development and Maintenance of Human Embryonic Stem Cell-Derived Hematopoietic Stem Cell-like Progenitors.

Zhou Y, Zhang Y, Chen B, Dong Y, Zhang Y, Mao B, Pan X, Lai M, Chen Y, Bian G, Zhou Q, Nakahata T, Zhou J, Wu M, Ma F.

Stem Cell Reports. 2019 Jul 9;13(1):31-47. doi: 10.1016/j.stemcr.2019.05.007. Epub 2019 Jun 6.

4.

Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions.

Matsubara H, Niwa A, Nakahata T, Saito MK.

Biochem Biophys Res Commun. 2019 Jul 12;515(1):1-8. doi: 10.1016/j.bbrc.2019.03.085. Epub 2019 Apr 2.

PMID:
30948156
5.

Verification and rectification of cell type-specific splicing of a Seckel syndrome-associated ATR mutation using iPS cell model.

Ichisima J, Suzuki NM, Samata B, Awaya T, Takahashi J, Hagiwara M, Nakahata T, Saito MK.

J Hum Genet. 2019 May;64(5):445-458. doi: 10.1038/s10038-019-0574-8. Epub 2019 Mar 8.

PMID:
30846821
6.

Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.

Taoka K, Arai S, Kataoka K, Hosoi M, Miyauchi M, Yamazaki S, Honda A, Aixinjueluo W, Kobayashi T, Kumano K, Yoshimi A, Otsu M, Niwa A, Nakahata T, Nakauchi H, Kurokawa M.

Sci Rep. 2018 Oct 26;8(1):15855. doi: 10.1038/s41598-018-34193-1.

7.

Efficient derivation of sympathetic neurons from human pluripotent stem cells with a defined condition.

Kirino K, Nakahata T, Taguchi T, Saito MK.

Sci Rep. 2018 Aug 27;8(1):12865. doi: 10.1038/s41598-018-31256-1.

8.

Lysosomal membrane permeabilization causes secretion of IL-1β in human vascular smooth muscle cells.

Ono H, Ohta R, Kawasaki Y, Niwa A, Takada H, Nakahata T, Ohga S, Saito MK.

Inflamm Res. 2018 Oct;67(10):879-889. doi: 10.1007/s00011-018-1178-z. Epub 2018 Aug 22.

9.

Panobinostat inhibits the proliferation of CD34+ CD38- cells under stimulation of hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.

Kurata T, Matsuda K, Hirabayashi K, Shigemura T, Sakashita K, Nakahata T, Koike K.

Pediatr Blood Cancer. 2018 Nov;65(11):e27261. doi: 10.1002/pbc.27261. Epub 2018 Jul 16.

PMID:
30014555
10.

Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress.

Honda-Ozaki F, Terashima M, Niwa A, Saiki N, Kawasaki Y, Ito H, Hotta A, Nagahashi A, Igura K, Asaka I, Li HL, Yanagimachi M, Furukawa F, Kanazawa N, Nakahata T, Saito MK.

Stem Cell Reports. 2018 Jun 5;10(6):1835-1850. doi: 10.1016/j.stemcr.2018.04.004. Epub 2018 May 3.

11.

Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS).

Hashii Y, Yoshida M, Hara J, Nishimura S, Yumura-Yagi K, Horibe K, Nakahata T.

J Pediatr Hematol Oncol. 2018 Jul;40(5):374-378. doi: 10.1097/MPH.0000000000001193.

PMID:
29697579
12.

RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells.

Mitsuda Y, Morita K, Kashiwazaki G, Taniguchi J, Bando T, Obara M, Hirata M, Kataoka TR, Muto M, Kaneda Y, Nakahata T, Liu PP, Adachi S, Sugiyama H, Kamikubo Y.

Sci Rep. 2018 Apr 23;8(1):6423. doi: 10.1038/s41598-018-24969-w.

13.

RUNX transcription factors potentially control E-selectin expression in the bone marrow vascular niche in mice.

Morita K, Tokushige C, Maeda S, Kiyose H, Noura M, Iwai A, Yamada M, Kashiwazaki G, Taniguchi J, Bando T, Hirata M, Kataoka TR, Nakahata T, Adachi S, Sugiyama H, Kamikubo Y.

Blood Adv. 2018 Mar 13;2(5):509-515. doi: 10.1182/bloodadvances.2017009324.

14.

Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists.

Nakahata T, Tokumaru K, Ito Y, Ishii N, Setoh M, Shimizu Y, Harasawa T, Aoyama K, Hamada T, Kori M, Aso K.

Bioorg Med Chem. 2018 May 1;26(8):1598-1608. doi: 10.1016/j.bmc.2018.02.005. Epub 2018 Feb 10.

PMID:
29478803
15.

Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors.

Oshima K, Saiki N, Tanaka M, Imamura H, Niwa A, Tanimura A, Nagahashi A, Hirayama A, Okita K, Hotta A, Kitayama S, Osawa M, Kaneko S, Watanabe A, Asaka I, Fujibuchi W, Imai K, Yabe H, Kamachi Y, Hara J, Kojima S, Tomita M, Soga T, Noma T, Nonoyama S, Nakahata T, Saito MK.

Biochem Biophys Res Commun. 2018 Mar 4;497(2):719-725. doi: 10.1016/j.bbrc.2018.02.139. Epub 2018 Feb 17.

16.

MEIS1 Regulates Hemogenic Endothelial Generation, Megakaryopoiesis, and Thrombopoiesis in Human Pluripotent Stem Cells by Targeting TAL1 and FLI1.

Wang H, Liu C, Liu X, Wang M, Wu D, Gao J, Su P, Nakahata T, Zhou W, Xu Y, Shi L, Ma F, Zhou J.

Stem Cell Reports. 2018 Feb 13;10(2):447-460. doi: 10.1016/j.stemcr.2017.12.017. Epub 2018 Jan 18.

17.

Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.

Morita K, Noura M, Tokushige C, Maeda S, Kiyose H, Kashiwazaki G, Taniguchi J, Bando T, Yoshida K, Ozaki T, Matsuo H, Ogawa S, Liu PP, Nakahata T, Sugiyama H, Adachi S, Kamikubo Y.

Sci Rep. 2017 Nov 30;7(1):16604. doi: 10.1038/s41598-017-16799-z.

18.

Inducible overexpression of RUNX1b/c in human embryonic stem cells blocks early hematopoiesis from mesoderm.

Chen B, Teng J, Liu H, Pan X, Zhou Y, Huang S, Lai M, Bian G, Mao B, Sun W, Zhou Q, Yang S, Nakahata T, Ma F.

J Mol Cell Biol. 2017 Aug 1;9(4):262-273. doi: 10.1093/jmcb/mjx032.

PMID:
28992293
19.

Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice.

Hitomi H, Kasahara T, Katagiri N, Hoshina A, Mae SI, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa A, Saito MK, Nakahata T, Nishiyama A, Osafune K.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaaj2300. doi: 10.1126/scitranslmed.aaj2300.

PMID:
28954928
20.

Microarray analyses of otospheres derived from the cochlea in the inner ear identify putative transcription factors that regulate the characteristics of otospheres.

Iki T, Tanaka M, Kitajiri SI, Kita T, Kawasaki Y, Mizukoshi A, Fujibuchi W, Nakagawa T, Nakahata T, Ito J, Omori K, Saito MK.

PLoS One. 2017 Jun 29;12(6):e0179901. doi: 10.1371/journal.pone.0179901. eCollection 2017.

21.

Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition.

Yamasaki T, Hirose H, Yamashita T, Takakura N, Morimoto S, Nakahata T, Kina A, Nakano Y, Okano Tamura Y, Sugama J, Odani T, Shimizu Y, Iwasaki S, Watanabe M, Maekawa T, Kasai S.

Bioorg Med Chem. 2017 Aug 1;25(15):4153-4162. doi: 10.1016/j.bmc.2017.06.003. Epub 2017 Jun 13.

PMID:
28622905
22.

Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages.

Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K, Osawa M, Nagahashi A, Semi K, Hotta A, Asaka I, Yamada Y, Nishikomori R, Heike T, Matsue H, Nakahata T, Saito MK.

J Allergy Clin Immunol. 2018 Jan;141(1):339-349.e11. doi: 10.1016/j.jaci.2017.04.013. Epub 2017 Jun 3.

PMID:
28587749
23.

Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.

Adachi R, Ogawa K, Matsumoto SI, Satou T, Tanaka Y, Sakamoto J, Nakahata T, Okamoto R, Kamaura M, Kawamoto T.

Eur J Med Chem. 2017 Aug 18;136:283-293. doi: 10.1016/j.ejmech.2017.04.067. Epub 2017 Apr 25.

PMID:
28505533
24.

Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists.

Tokumaru K, Ito Y, Nomura I, Nakahata T, Shimizu Y, Kurimoto E, Aoyama K, Aso K.

Bioorg Med Chem. 2017 Jun 15;25(12):3098-3115. doi: 10.1016/j.bmc.2017.03.064. Epub 2017 Apr 1.

PMID:
28433511
25.

Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.

Kato I, Nishinaka Y, Nakamura M, Akarca AU, Niwa A, Ozawa H, Yoshida K, Mori M, Wang D, Morita M, Ueno H, Shiozawa Y, Shiraishi Y, Miyano S, Gupta R, Umeda K, Watanabe K, Koh K, Adachi S, Heike T, Saito MK, Sanada M, Ogawa S, Marafioti T, Watanabe A, Nakahata T, Enver T.

Blood. 2017 Jun 8;129(23):3126-3129. doi: 10.1182/blood-2016-06-721712. Epub 2017 Apr 19. No abstract available.

26.

Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia.

Morita M, Nishinaka Y, Kato I, Saida S, Hiramatsu H, Kamikubo Y, Heike T, Nakahata T, Adachi S.

Int J Hematol. 2017 Mar;105(3):335-340. doi: 10.1007/s12185-016-2137-5. Epub 2016 Nov 15.

PMID:
27848186
27.

Laminin-guided highly efficient endothelial commitment from human pluripotent stem cells.

Ohta R, Niwa A, Taniguchi Y, Suzuki NM, Toga J, Yagi E, Saiki N, Nishinaka-Arai Y, Okada C, Watanabe A, Nakahata T, Sekiguchi K, Saito MK.

Sci Rep. 2016 Nov 2;6:35680. doi: 10.1038/srep35680.

28.

Identification of a High-Frequency Somatic NLRC4 Mutation as a Cause of Autoinflammation by Pluripotent Cell-Based Phenotype Dissection.

Kawasaki Y, Oda H, Ito J, Niwa A, Tanaka T, Hijikata A, Seki R, Nagahashi A, Osawa M, Asaka I, Watanabe A, Nishimata S, Shirai T, Kawashima H, Ohara O, Nakahata T, Nishikomori R, Heike T, Saito MK.

Arthritis Rheumatol. 2017 Feb;69(2):447-459. doi: 10.1002/art.39960.

29.

Early Development of Definitive Erythroblasts from Human Pluripotent Stem Cells Defined by Expression of Glycophorin A/CD235a, CD34, and CD36.

Mao B, Huang S, Lu X, Sun W, Zhou Y, Pan X, Yu J, Lai M, Chen B, Zhou Q, Mao S, Bian G, Zhou J, Nakahata T, Ma F.

Stem Cell Reports. 2016 Nov 8;7(5):869-883. doi: 10.1016/j.stemcr.2016.09.002. Epub 2016 Oct 6.

30.

A portable platform for stepwise hematopoiesis from human pluripotent stem cells within PET-reinforced collagen sponges.

Sugimine Y, Niwa A, Matsubara H, Kobayashi K, Tabata Y, Heike T, Nakahata T, Saito MK.

Int J Hematol. 2016 Dec;104(6):647-660. Epub 2016 Sep 6.

PMID:
27599982
31.

Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models.

Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, Toyoda T, Matsui S, Araoka T, Yasuno T, Mae S, Kobayashi H, Kondo N, Kitaoka F, Amano N, Arai S, Ichisaka T, Matsuura N, Inoue S, Yamamoto T, Takahashi K, Asaka I, Yamada Y, Ubara Y, Muso E, Fukatsu A, Watanabe A, Sato Y, Nakahata T, Mori Y, Koizumi A, Nakao K, Yamanaka S, Osafune K.

Sci Rep. 2016 Jul 15;6:30013. doi: 10.1038/srep30013.

32.

CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.

Nodomi S, Umeda K, Saida S, Kinehara T, Hamabata T, Daifu T, Kato I, Hiramatsu H, Watanabe KI, Kuwahara Y, Iehara T, Adachi S, Konishi E, Nakahata T, Hosoi H, Heike T.

Oncogene. 2016 Oct 6;35(40):5317-5327. doi: 10.1038/onc.2016.72. Epub 2016 Apr 4.

33.

High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.

Takahashi H, Watanabe T, Kinoshita A, Yuza Y, Moritake H, Terui K, Iwamoto S, Nakayama H, Shimada A, Kudo K, Taki T, Yabe M, Matsushita H, Yamashita Y, Koike K, Ogawa A, Kosaka Y, Tomizawa D, Taga T, Saito AM, Horibe K, Nakahata T, Miyachi H, Tawa A, Adachi S.

Br J Haematol. 2016 Aug;174(3):437-43. doi: 10.1111/bjh.14068. Epub 2016 Mar 31.

PMID:
27029412
34.

Mislocalization of syntaxin-1 and impaired neurite growth observed in a human iPSC model for STXBP1-related epileptic encephalopathy.

Yamashita S, Chiyonobu T, Yoshida M, Maeda H, Zuiki M, Kidowaki S, Isoda K, Morimoto M, Kato M, Saitsu H, Matsumoto N, Nakahata T, Saito MK, Hosoi H.

Epilepsia. 2016 Apr;57(4):e81-6. doi: 10.1111/epi.13338. Epub 2016 Feb 25.

35.

Establishment of isogenic iPSCs from an individual with SCN1A mutation mosaicism as a model for investigating neurocognitive impairment in Dravet syndrome.

Maeda H, Chiyonobu T, Yoshida M, Yamashita S, Zuiki M, Kidowaki S, Isoda K, Yamakawa K, Morimoto M, Nakahata T, Saito MK, Hosoi H.

J Hum Genet. 2016 Jun;61(6):565-9. doi: 10.1038/jhg.2016.5. Epub 2016 Feb 4.

PMID:
26841829
36.

Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.

Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Nakahata T, Heike T, Sugita K, Inukai T.

Mol Cancer Ther. 2016 Jan;15(1):94-105. doi: 10.1158/1535-7163.MCT-14-1065. Epub 2015 Dec 4.

37.

Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.

Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Shimada A, Taki T, Toki T, Ito E, Goto H, Koh K, Saito AM, Horibe K, Nakahata T, Tawa A, Adachi S.

Pediatr Blood Cancer. 2016 Feb;63(2):248-54. doi: 10.1002/pbc.25789. Epub 2015 Oct 20.

PMID:
26481183
38.

Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.

Shoji E, Sakurai H, Nishino T, Nakahata T, Heike T, Awaya T, Fujii N, Manabe Y, Matsuo M, Sehara-Fujisawa A.

Sci Rep. 2015 Aug 20;5:12831. doi: 10.1038/srep12831.

39.

Erratum to: Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan.

Moriwaki K, Manabe A, Taketani T, Kikuchi A, Nakahata T, Hayashi Y.

Int J Hematol. 2015 Aug;102(2):249. doi: 10.1007/s12185-015-1834-9.

PMID:
26177587
40.

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.

Nakano S, Tsukimura T, Togawa T, Ohashi T, Kobayashi M, Takayama K, Kobayashi Y, Abiko H, Satou M, Nakahata T, Warnock DG, Sakuraba H, Shibasaki F.

PLoS One. 2015 Jun 17;10(6):e0128351. doi: 10.1371/journal.pone.0128351. eCollection 2015.

41.

Disease modeling using induced pluripotent stem cells (general remarks).

Nakahata T.

Nihon Rinsho. 2015 Jun;73 Suppl 5:374-80. Japanese. No abstract available.

PMID:
30458082
42.

Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs.

Yoshida M, Kitaoka S, Egawa N, Yamane M, Ikeda R, Tsukita K, Amano N, Watanabe A, Morimoto M, Takahashi J, Hosoi H, Nakahata T, Inoue H, Saito MK.

Stem Cell Reports. 2015 Apr 14;4(4):561-8. doi: 10.1016/j.stemcr.2015.02.010. Epub 2015 Mar 19.

43.

Pluripotent cell models of fanconi anemia identify the early pathological defect in human hemoangiogenic progenitors.

Suzuki NM, Niwa A, Yabe M, Hira A, Okada C, Amano N, Watanabe A, Watanabe K, Heike T, Takata M, Nakahata T, Saito MK.

Stem Cells Transl Med. 2015 Apr;4(4):333-8. doi: 10.5966/sctm.2013-0172. Epub 2015 Mar 11.

44.

Prognostic significance of aminopeptidase-N (CD13) in hepatoblastoma.

Saida S, Watanabe K, Kato I, Fujino H, Umeda K, Okamoto S, Uemoto S, Hishiki T, Yoshida H, Tanaka S, Adachi S, Niwa A, Nakahata T, Heike T.

Pediatr Int. 2015 Aug;57(4):558-66. doi: 10.1111/ped.12597. Epub 2015 Jul 14.

PMID:
25682862
45.

Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media.

Fukuta M, Nakai Y, Kirino K, Nakagawa M, Sekiguchi K, Nagata S, Matsumoto Y, Yamamoto T, Umeda K, Heike T, Okumura N, Koizumi N, Sato T, Nakahata T, Saito M, Otsuka T, Kinoshita S, Ueno M, Ikeya M, Toguchida J.

PLoS One. 2014 Dec 2;9(12):e112291. doi: 10.1371/journal.pone.0112291. eCollection 2014.

46.

Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway.

Yokoyama K, Ikeya M, Umeda K, Oda H, Nodomi S, Nasu A, Matsumoto Y, Izawa K, Horigome K, Kusaka T, Tanaka T, Saito MK, Yasumi T, Nishikomori R, Ohara O, Nakayama N, Nakahata T, Heike T, Toguchida J.

Arthritis Rheumatol. 2015 Jan;67(1):302-14. doi: 10.1002/art.38912.

47.

Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan.

Moriwaki K, Manabe A, Taketani T, Kikuchi A, Nakahata T, Hayashi Y.

Int J Hematol. 2014 Nov;100(5):478-84. doi: 10.1007/s12185-014-1674-z. Epub 2014 Sep 27. Erratum in: Int J Hematol. 2015 Aug;102(2):249.

PMID:
25261124
48.

In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.

Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, Ebihara Y, Ma F, Matsuda K, Saito S, Hirabayashi K, Kurata T, Uyen LT, Nakazawa Y, Tsuji K, Heike T, Nakahata T, Koike K.

Leukemia. 2015 Mar;29(3):606-14. doi: 10.1038/leu.2014.239. Epub 2014 Aug 8.

PMID:
25102944
49.

Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification.

Hasegawa D, Chen X, Hirabayashi S, Ishida Y, Watanabe S, Zaike Y, Tsuchida M, Masunaga A, Yoshimi A, Hama A, Kojima S, Ito M, Nakahata T, Manabe A.

Br J Haematol. 2014 Sep;166(5):758-66. doi: 10.1111/bjh.12955. Epub 2014 Jun 4.

PMID:
24894311
50.

Multicolor staining of globin subtypes reveals impaired globin switching during erythropoiesis in human pluripotent stem cells.

Ochi K, Takayama N, Hirose S, Nakahata T, Nakauchi H, Eto K.

Stem Cells Transl Med. 2014 Jul;3(7):792-800. doi: 10.5966/sctm.2013-0216. Epub 2014 May 29.

Supplemental Content

Loading ...
Support Center